---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004858"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:26:40.548277+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025

## Summary
- Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).
- Cash, cash equivalents and marketable securities $1.1B as of Dec 31, 2022, up from $965.6M at Dec 31, 2021.
- R&D expenses $86.3M in Q4 2022, down from $96.8M in Q4 2021; G&A expenses $22.7M vs $17.8M.
- Pipeline milestones: BEAM-101 sentinel cohort enrollment to finish 2023, BEAM-201 first patient dosing by mid-2023, BEAM-301 and BEAM-302 regulatory filings in late 2023/early 2024.
- North Carolina manufacturing facility expected to commence cGMP operations in late 2023.

## SEC filing metadata
- accession: 0000950170-23-004858
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/0000950170-23-004858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/beam-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004858
- JSON: https://secwatch.observer/filing/0000950170-23-004858.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004858.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported the fourth quarter of 2022 results: net income Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022, EPS $0.54 per share. Guidance reaffirmed.
  - Period: the fourth quarter of 2022
  - Net income: Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022
  - EPS: $0.54 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: issued a press release announcing the Company’s financial results for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023004858/0000950170-23-004858-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.